Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2799-2813

  Lilius, T O ^a   Jokinen, V ^a   Neuvonen, M S ^b   Niemi, M ^b,c   Kalso, E A ^a,c   Rauhala, P V ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; MORPHINE; MORPHINE 3 GLUCURONIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORKETAMINE; UNCLASSIFIED DRUG; ANALGESIC AGENT; MORPHINE DERIVATIVE; MORPHINE-3-GLUCURONIDE; NARCOTIC ANALGESIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT PLATE TEST; LIVER LEVEL; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RAT; ROTAROD TEST; TAIL FLICK TEST; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG TOLERANCE; LIVER; METABOLISM; PAIN; PAIN MEASUREMENT; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; INJECTIONS, SUBCUTANEOUS; KETAMINE; LIVER; MORPHINE; MORPHINE DERIVATIVES; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84929190685     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12974     Document Type: Article

References (57)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, CGTP Collaborators et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated ion channels. Br J Pharmacol 170: 1582-1606.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796
4. Amphoux A, Vialou V, Drescher E, Brüss M, La Cour CM, Rochat C, et al. (2006). Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50: 941-952.
5. Arroyo-Novoa CM, Figueroa-Ramos MI, Miaskowski C, Padilla G, Paul SM, Rodríguez-Ortiz P, et al. (2011). Efficacy of small doses of ketamine with morphine to decrease procedural pain responses during open wound care. Clin J Pain 27: 561-566.
6. Bell RF, (1999). Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 83: 101-103.
7. Bell RF, (2012). Ketamine for chronic noncancer pain: concerns regarding toxicity. Curr Opin Support Palliat Care 6: 183-187.
8. Bell RF, Dahl JB, Moore RA, Kalso EA, (2006). Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev (1): CD004603.
9. Bell RF, Eccleston C, Kalso EA, (2012). Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev (11): CD003351.
10. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13: e58-e68.
11. Coffman BL, Rios GR, Tephly TR, (1996). Purification and properties of two rat liver phenobarbital-inducible UDP-glucuronosyltransferases that catalyze the glucuronidation of opioids. Drug Metab Dispos 24: 329-333.
12. Coffman BL, Rios GR, King CD, Tephly TR, (1997). Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25: 1-4.
13. Doan KMM, (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303: 1029-1037.
14. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. (2007). Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132: 237-251.
15. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM, (1997). Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333: 99-104.
16. Edwards SR, Minto CF, Mather LE, (2002). Concurrent ketamine and alfentanil administration: pharmacokinetic considerations. Br J Anaesth 88: 94-100.
17. González P, Cabello P, Germany A, Norris B, Contreras E, (1997). Decrease of tolerance to physical dependence on morphine by, glutamate receptor antagonists. Eur J Pharmacol 332: 257-262.
18. Grant IS, Nimmo WS, Clements JA, (1981). Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53: 805-810.
19. Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, et al. (2012). Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 30: 3611-3617.
20. Hassan HE, Myers AL, Lee IJ, Mason CW, Wang D, Sinz MW, et al. (2013). Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone. Drug Metab Dispos 41: 1060-1069.
21. Hijazi Y, (2002). Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30: 853-858.
22. Holtman JR, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP, (2008a). Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 90: 676-685.
23. Holtman JR, Crooks P, Johnson-Hardy JK, Wala E, (2008b). Interaction between morphine and norketamine enantiomers in rodent models of nociception. Pharmacol Biochem Behav 90: 769-777.
24. Honarmand A, Safavi M, Karaky H, (2012). Preincisional administration of intravenous or subcutaneous infiltration of low-dose ketamine suppresses postoperative pain after appendectomy. J Pain Res 5: 1-6.
25. Kavalali ET, Monteggia LM, (2012). Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 169: 1150-1156.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
27. King CD, Rios GR, Green MD, MacKenzie PI, Tephly TR, (1997). Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. Drug Metab Dispos 25: 251-255.
28. Laskowski K, Stirling A, McKay WP, Lim HJ, (2011). A systematic review of intravenous ketamine for postoperative analgesia. Can J Anesth 58: 911-923.
29. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL, (1999). Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27: 827-834.
30. Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, et al. (2013). The CYP2B6∗6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos 41: 1264-1272.
31. Mathews TJ, Churchhouse AMD, Housden T, Dunning J, (2012). Does adding ketamine to morphine patient-controlled analgesia safely improve post-thoracotomy pain? Interact Cardiovasc Thorac Surg 14: 194-199.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Miyamoto H, Saito Y, Kirihara Y, Hara K, Sakura S, Kosaka Y, (2000). Spinal coadministration of ketamine reduces the development of tolerance to visceral as well as somatic antinociception during spinal morphine infusion. Anesth Analg 90: 136-141.
34. Morgan CJA, Curran HV, Independent Scientific Committee on Drugs (2012). Ketamine use: a review. Addiction 107: 27-38.
35. Nesher N, Ekstein MP, Paz Y, Marouani N, Chazan S, Weinbroum AA, (2009). Morphine with adjuvant ketamine vs higher dose of morphine alone for immediate postthoracotomy analgesia. Chest 136: 245-252.
36. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
37. Pritchard M, Fournel-Gigleux S, Siest G, Mackenzie P, Magdalou J, (1994). A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids. Mol Pharmacol 45: 42-50.
38. Qi X, Evans AM, Wang J, Miners JO, Upton RN, Milne RW, (2010). Inhibition of morphine metabolism by ketamine. Drug Metab Dispos 38: 728-731.
39. Salas S, Frasca M, Planchet-Barraud B, Burucoa B, Pascal M, Lapiana J-M, et al. (2012). Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med 15: 287-293.
40. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P, (1995). Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705.
41. Sharma HS, Ali SF, (2006). Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci 1074: 198-224.
42. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE, (1999). Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 81: 85-93.
43. Shimoyama N, Shimoyama M, Inturrisi CE, Elliott KJ, (1996). Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology 85: 1357-1366.
44. Sinner B, Graf BM, (2008) Ketamine. In:, Schuttler J, Schwilden H, (eds). Modern Anesthetics. Springer: Berlin Heidelberg, pp. 313-333.
45. Su W, Pasternak GW, (2013). The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia. Synapse 67: 609-619.
46. Suppa E, Valente A, Catarci S, Zanfini B, Draisci G, (2012). A study of low-dose S-Ketamine infusion as 'preventive' pain treatment for cesarean section with spinal anesthesia: benefits and side effects. Minerva Anestesiol 7: 774-781.
47. Trujillo KA, Akil H, (1991). Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251: 85-87.
48. Trujillo KA, Akil H, (1994). Inhibition of opiate tolerance by non-competitive N-d-aspartate receptor antagonists. Brain Res 633: 178-188.
49. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J, (2013). Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 86: 666-678.
50. Uchaipichat V, Raungrut P, Chau N, Janchawee B, Evans AM, Miners JO, (2011). Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. Drug Metab Dispos 39: 1324-1328.
51. Vachon P, Hélie P, Veilleux-Lemieux D, Beaudry F, (2012). Effects of endotoxemia on the pharmacodynamics and pharmacokinetics of ketamine and xylazine anesthesia in Sprague-Dawley rats. Vet Med Res Rep 3: 99-109.
52. Varma MVS, Sateesh K, Panchagnula R, (2005). Functional role of p-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharmaceutics 2: 12-21.
53. Visser E, Schug SA, (2006). The role of ketamine in pain management. Biomed Pharmacother 60: 341-348.
54. White PF, (1988). Clinical pharmacology of intravenous induction drugs. Int Anesthesiol Clin 26: 98-104.
55. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC, (1999). The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 128: 563-568.
56. Zheng M, McErlane KM, Ong MC, (1998). High-performance liquid chromatography-mass spectrometry-mass spectrometry analysis of morphine and morphine metabolites and its application to a pharmacokinetic study in male Sprague-Dawley rats. J Pharm Biomed Anal 16: 971-980.
57. Zimmermann M, (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.